KITE : Summary for Kite Pharma, Inc. - Yahoo Finance

U.S. Markets closed

Kite Pharma, Inc. (KITE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
76.84+2.34 (+3.14%)
At close: 4:00PM EDT
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close74.50
Bid74.10 x 100
Ask78.00 x 100
Day's Range74.58 - 77.75
52 Week Range39.82 - 88.58
Avg. Volume1,465,457
Market Cap4.21B
PE Ratio (TTM)-14.08
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Zacks Small Cap Research5 days ago

    CYRX: Growth in Clinical Trial Customers Pushing Revenue To Record Heights

    Cryoport (CYRX) reported financial results for their fiscal 2017 third quarter ending December 31st.  (Note that the company is transitioning their fiscal year to that of the calendar year –  our model beginning with this report reflects the new calendar-year reporting.  CYRX has filed a 10-KT Transition Report and will begin reporting under the calendar year format beginning with the period ending March 31, which will now represent their first quarter). Q3 revenue, at $2.2M, was up 53% yoy and about 5% higher than our estimate.  It is also a new record and up almost 13% sequentially from fiscal Q2 ’17.  Results in the period ending December 31st shows that revenue has come in slightly better than our estimates for the third straight quarter with operating loss much better than our numbers for the second period in a row.  While the specific reasons behind the revenue beat is tough to pinpoint, better than anticipated performance of the animal health and reproductive medicine segments has been a contributor.

  • Motley Fool8 days ago

    Why Kite Pharma Stock Is Already Up 62% This Year

    The potential to commercialize an entirely new approach to battling cancer is sparking a big rally in this biotech upstart.

  • Business Wire9 days ago

    Kite Announces Appointment of Renowned Cancer Researcher, Owen N. Witte, M.D., to its Board of Directors

    Kite Pharma, Inc. today announced that Owen N. Witte, M.D., the founding director of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at the University of California Los Angeles and a renowned cancer researcher, has been appointed to its Board of Directors.